Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia

被引：2

作者：

De Botton, Stephane ^{[1
]}

Yee, Karen ^{[2
]}

Recher, Christian ^{[3
]}

Wei, Andrew H. ^{[4
]}

Montesinos, Pau ^{[5
]}

Taussig, David ^{[6
]}

Pigneux, Arnaud ^{[7
]}

Braun, Thorsten ^{[8
]}

Curti, Antonio ^{[9
]}

Esteve, Jordi ^{[10
]}

Grove, Carolyn ^{[11
]}

Jonas, Brian A. ^{[12
]}

Khwaja, Asim ^{[13
,14
]}

Legrand, Olivier ^{[15
]}

Peterlin, Pierre ^{[16
]}

Sangerman, Montserrat Arnan ^{[17
]}

Blum, William G. ^{[18
]}

Cilloni, Daniela ^{[19
]}

Hiwase, Devendra ^{[20
]}

Jurcic, Joseph G. ^{[21
]}

Krauter, Jurgen ^{[22
]}

Thomas, Xavier ^{[23
]}

Watts, Justin ^{[24
]}

Yang, Jay ^{[25
]}

Xin, Zihao ^{[26
]}

Sedkov, Alex ^{[26
]}

Guichard, Sylvie ^{[26
]}

Sweeney, Jennifer ^{[26
]}

Marzac, Christophe ^{[27
]}

Cortes, Jorge E. ^{[28
]}

Fenaux, Pierre ^{[29
]}

机构：

[1] Inst Gustave Roussy, Dept Haematol, Villejuif, France

[2] Princess Margaret Canc Ctr, Toronto, ON, Canada

[3] Inst Univ Canc Toulouse Oncopole, Paris, France

[4] Alfred Hosp, Dept Haematol, Melbourne, Australia

[5] Hosp Univ Politecn La Fe Valencia, Dept Hematol, Valencia, Spain

[6] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England

[7] Univ Bordeaux, Dept Hematol, Ctr HospUniv CHU Bordeaux, Bordeaux, France

[8] Paris XIII Univ, Hop Avicenne, AP HP, Bobigny, France

[9] IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

[10] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain

[11] PathWest Sir Charles Gairdner Hosp, Dept Haematol, Dept Hlth, Nedlands, WA, Australia

[12] Univ Calif Davis, Div Hematol & Oncol, Dept Internal Med, Davis, CA USA

[13] Univ Coll London Hosp, London, England

[14] Univ Coll Canc Inst, London, England

[15] St Antoine Univ Hosp, Dept Hematol, Paris, France

[16] CHU Nantes, Serv Hematol Clin, Nantes, France

[17] IDIBELL, Inst Catala Oncol, Hosp Duran & Reynals, Clin Hematol Dept, Barcelona, Spain

[18] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[19] Univ Turin, Dept Clin & Biol Sci, Turin, Italy

[20] Royal Adelaide Hosp, Dept Haematol, Adelaide, SA, Australia

[21] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Med Ctr, New York, NY USA

[22] Braunschweig Municipal Hosp, Dept Internal Med 3, Braunschweig, Germany

[23] Lyon Sud Univ Hosp, Hosp Civils Lyon, Dept Hematol, Pierre Benite, France

[24] Univ Miami, Dept Med, Leukemia Program, Sylvester Comprehens Canc Ctr, Miami, FL USA

[25] Karmanos Canc Inst, Dept Oncol, Detroit, MI USA

[26] Forma Therapeut Inc, Watertown, MA USA

[27] Univ Paris Saclay, Dept Biol pathol, Gustave Roussy, Villejuif, France

[28] Georgia Canc Ctr, Augusta, GA USA

[29] St Louis Hosp, Dept Haematol, Paris, France

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-144912

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2351

引用

页数：9

共 50 条

[41] EXPOSURE-RESPONSE ANALYSIS OF IVOSIDENIB IN PATIENTS WITH IDH1-MUTANT RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA.
Le, K.
Kleijn, H. J.
Dai, D.
Fan, B.
Liu, H.
Attar, E. C.
Hickman, D.
Agresta, S. V.
Yang, H.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S85 - S85
[42] MOLECULAR PREDICTORS OF RESPONSE AND OUTCOME IN PATIENTS WITH REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA RECEIVING VENETOCLAX PLUS NON-INTENSIVE CHEMOTHERAPY
Krueger, K.
Beutel, G.
Gabdoulline, R.
Koenecke, C.
Stadler, M.
Gohring, G.
Behrens, Y.
Trummer, A.
Krauter, J.
Kaun, S.
Voss, A.
Goetze, K.
Braitsch, K.
Wichmann, M.
Thol, F.
Heuser, M.
Shahswar, R.
ANNALS OF HEMATOLOGY, 2023, 102 (SUPPL 1) : S41 - S41
[43] Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia
Wang, Eunice S.
Yee, Karen
Koh, Liang Piu
Hogge, Donna
Enschede, Sari
Carlson, Dawn M.
Dudley, Atthew
Glaser, Keith
McKeegan, Evelyn
Albert, Daniel H.
Li, Xiaohui
Pradhan, Rajendra
Stock, Wendy
LEUKEMIA & LYMPHOMA, 2012, 53 (08) : 1543 - 1551
[44] Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia
DeAngelo, Daniel J.
Jonas, Brian A.
Liesveld, Jane L.
Bixby, Dale L.
Advani, Anjali S.
Marlton, Paula
Magnani, John L.
Thackray, Helen M.
Feldman, Eric J.
O'Dwyer, Michael E.
Becker, Pamela S.
BLOOD, 2022, 139 (08) : 1135 - 1146
[45] A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia
Jonas, Brian A.
Hou, Jing-Zhou
Roboz, Gail J.
Alvares, Caroline L.
Jeyakumar, Deepa
Edwards, John R.
Erba, Harry P.
Kelly, Richard J.
Roellig, Christoph
Fiedler, Walter
Brackman, Deanna
Siddani, Satya R.
Chyla, Brenda
Hilger-Rolfe, Jacqueline
Watts, Justin M.
HEMATOLOGICAL ONCOLOGY, 2023, 41 (04) : 743 - 752
[46] Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study
Kensuke Usuki
Hiroshi Handa
Ilseung Choi
Takahiro Yamauchi
Hiroatsu Iida
Tomoko Hata
Shoichi Ohwada
Noriko Okudaira
Kota Nakamura
Sakura Sakajiri
International Journal of Hematology, 2019, 110 : 654 - 664
[47] Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study
Usuki, Kensuke
Handa, Hiroshi
Choi, Ilseung
Yamauchi, Takahiro
Iida, Hiroatsu
Hata, Tomoko
Ohwada, Shoichi
Okudaira, Noriko
Nakamura, Kota
Sakajiri, Sakura
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (06) : 654 - 664
[48] Identification of molecular predictors of response to ZARNESTRA™ (tipifarnib, R115777) in relapsed and refractory acute myeloid leukemia.
Raponi, M
Lowenberg, B
Lancet, JE
Harousseau, JL
Stone, R
Rackoff, W
Thibault, A
Zhang, Y
Atkins, D
Wang, YX
BLOOD, 2004, 104 (11) : 246A - 246A
[49] RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed/refractory acute myeloid leukemia
Chow, Signy
Tang, Kenny
Al-Abri, Mahmood
Hall, Victoria
Tremblay-Lemay, Rosemarie
Rashedi, Iran
Tsui, Hubert
Chan, Steven M.
LEUKEMIA RESEARCH, 2021, 111
[50] A Phase 1 Trial of Valemetostat in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
Erba, Harry P.
Oluwole, Olalekan O.
Bixby, Dale
Rampal, Raajit K.
Fathi, Amir T.
Paliwal, Prashni
Jin, Jin
Inoue, Ai
Daver, Naval
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S311 - S312

← 1 2 3 4 5 →